Abstract The chromosome 21 gene RCAN1, encoding a modulator of the calcineurin (CaN) phosphatase, is a candidate gene for contributing to cognitive disability in people with Down syndrome (DS; trisomy 21). To develop a physiologically relevant model for studying the biochemistry of RCAN1 and its contribution to DS, we generated bacterial artificial chromosome-transgenic (BAC-Tg) mouse lines containing the human RCAN1 gene with a C-terminal HA-FLAG epitope tag incorporated by recombineering. The BAC-Tg was expressed at levels only moderately higher than the native Rcan1 gene: approximately 1.5-fold in RCAN1
Introduction
Down syndrome (DS), with an incidence of one in 700 live births, is caused by trisomy of human chromosome 21 (Antonarakis et al. 2004) . DS phenotypes include cognitive disability, early-onset Alzheimer's disease (AD), congenital heart defects, increased autoimmunity and mild immunodeficiency, and an increased incidence of leukemia in early childhood. In contrast to the leukemia predisposition, children and adults with DS have fewer solid tumors than the general population. The DS Critical Region 1 (DSCR1) gene [currently named regulator of calcineurin 1 (RCAN1)] maps to chromosome band 21q22.12 and encodes a regulatory protein in the calcineurin (CaN)/NFAT signaling pathway. Both positive and negative effects of RCAN1 on CaN phosphatase activity have been reported, probably reflecting a biphasic dose-response (Chan et al. 2005; Fuentes et al. 2000; Hilioti et al. 2004; Kingsbury and Cunningham 2000; Rothermel et al. 2000; Sanna et al. 2006) . The RCAN1 gene consists of seven exons plus the alternative first one (Davies et al. 2007) and produces several mRNA isoforms through alternative splicing. In this report we refer to the isoform with 252 amino acids (NP_004405) as the long isoform, and the isoform with 197 amino acids (NP_981963) as the short isoform. RCAN1 is expressed in human brain, heart, mammary gland, skeletal muscle, and other organs (Ermak et al. 2001; Fuentes et al. 1997) . It is overexpressed in the brain of DS fetuses, roughly in proportion to its 1.5-fold increased copy number (Fuentes et al. 2000) , and its expression is increased with aging and in Alzheimer's disease (Cook et al. 2005) .
Overexpression of RCAN1 from cDNA-based transgenes (Tg's) in mice produced cardiac and brain phenotypes (Ma et al. 2004) , while overexpression and deletion of nebula, an ortholog of human RCAN1, disrupted olfactory learning and long-term memory in Drosophila (Chang et al. 2003) . Deletion of the Rcan1 and Rcan2 genes from mice also produced a behavioral phenotype, and biochemical assays in these and other studies have led to a working model for dosage-dependent function of this CaN-interacting protein, in which some expression of RCAN1 is essential for and stimulates CaN function, while higher levels can be inhibitory (Sanna et al. 2006; Vega et al. 2003) . A role for RCAN1 overexpression and deficiency in establishing the ''set point'' for CaN-dependent cardiac hypertrophy has been extensively investigated, and several studies using cDNA expression vectors and gene knockout have implicated RCAN1 as a regulator of tumor angiogenesis and a candidate tumor suppressor gene, albeit with different effects depending on the experimental system (Hesser et al. 2004; Iizuka et al. 2004; Minami et al. 2004; Vega et al. 2003) . In undertaking the current study we reasoned that to fully understand the biochemistry and physiological role of RCAN1 in normal tissues and in DS, it would be essential to utilize in vivo models with the RCAN1 gene overexpressed at levels that are comparable to the moderate copy-number-dependent overexpression of this gene in human DS, and to stably express epitope-tagged versions of this protein which would allow its biochemical interactions to be studied in native tissues. Here we describe the production of bacterial artificial chromosome-transgenic (BAC-Tg) mice that overexpress epitope-tagged human RCAN1 at physiological levels and we use tissues from these mice to study the biochemistry and function of RCAN1.
Materials and methods
BAC recombineering and production of BAC-Tg mice BAC DNA was prepared by double potassium acetate precipitation followed by CsCl gradient separation (Xing et al. 2007) . A short tandem tag containing the sequence encoding HA and FLAG peptides (17 amino acids total) was inserted prior to the stop codon of the last exon of RCAN1 in BAC RPCI-11-272A3 using homologous recombination. BAC recombineering was performed in EL250 (Lee et al. 2001) cells electroporated with BAC DNA. A PCR cassette was introduced into these cells, which were cultured at 42°C for 15 min to induce expression of the Flpe recombinase. The PCR cassette contains the tandem tag and kanamycin selection marker and is flanked by 60 bp sequences on each side which are homologous to the sequence of the insertion site on the BAC. The following primers were used: TG-left, GACCTAAGCCAAAAATTATCCAGACCAGGAGGCC GGAGTACACGCCGATCCACCTCAGCTACCCTTAT GACGTGCCCGAT; and TG-right, AGTAAAAGATTC CTCCCGTGAGTATGATTTGGAATGCGTCCTCGTC GCGTGCCAGTTCATTTGGAGGCTACCATGGAGAA. The plasmid pIGCN21 (Lee et al. 2001 ) was used to provide the Frt-kan-Frt cassette. Kanamycin-resistant BAC clones were induced by L-arabinose to remove the kanamycin marker so that only the tandem tag was left in the final modified BAC. The BAC DNA (1 ng/ll in circular form) was injected into 200 pronuclei of fertilized oocytes of C57BL/69CBA mice, and the oocytes were transferred to pseudopregnant Swiss Webster foster mothers. All mice used in this study were housed in an AAALAC-accredited facility and all procedures relating to the care and use of animals were performed in accordance with the National Institutes of Health guidelines at Columbia University. p53 flex7 (Chen et al. 2005) and Wap cre mice (Ludwig et al. 2001) were described previously.
Southern and northern blotting
Genomic DNA was prepared by lysing the tissue in SDS/ proteinase K, incubating for several hours at 50°C, followed by phenol/chloroform extraction and precipitation in ethanol. The Southern blots for copy number analysis were cohybridized with genomic probes specific to human RCAN1 and a mouse probe for the Col6a1 gene, located on mouse chromosome 16 and designed to hybridize to a conveniently sized restriction fragment in the same lanes. PCR primers for synthesizing the human RCAN1 probe for Southern blotting were Hu-Dscr-left: 5 0 -CCGTCAGCTCC TCATTTCTC-3 0 , and Hu-Dscr-right: 5 0 -CCCAGGAGAG CTTCCTACCT-3 0 . RNA was prepared after solubilizing tissues in Trizol reagent (Invitrogen, Carlsbad, CA) according to the protocol of the manufacturer. RNA was prepared from different tissues of Tg and littermate wildtype adult mice, and 5 lg RNA was used for Northern blotting followed by hybridization of the blots with probes specific for the last exon of human RCAN1 or mouse Rcan1. The primers for generating the Northern probes were mouse For, 5 0 -CCGTGTGGAATTGTCCTTCT-3 0 , mouse Rev,
0 , and human Rev, 5 0 -TCA GGAATGAATGGGGAAAG-3 0 .
Western blotting
Tissues were lysed in cold RIPA buffer (50 mM Tris, 150 mM NaCl, 0.1 % SDS, 0.5 % sodium deoxycholate, 1 % NP40) and centrifuged to remove insoluble debris. Total cell extracts normalized for protein content were boiled for 5 min in a denaturing solution containing 12 mmol/L Tris (pH 6.8), 5 % glycerol, 0.4 % SDS, 3 mmol/L 2-mercaptomethanol, and 0.02 % bromophenol blue. Of the protein lysate, 50 lg per sample was electrophoresed on PAGE gels (Invitrogen). Primary antibodies were Anti-HA (Roche Applied Science, 11867423001), anti-FLAG M2 (Sigma, F1804), anti-RCAN1 antibody (Abnova, H00001827-M0; recognizing both human and mouse RCAN1), anti-calcineurin (BD Biosciences, 556350), anti-GSK3b (Chemicon, AB8687), anti-phospho-DARPP32 (RD Systems, VUPO1), anti-phospho-Tau (Ser 396) (Spring Biosciences, E12124), anti-phospho-CREB (Ser133) (Cell Signaling Technology, 9191S), anti-phosphodynamin (Affinity Bioreagents, PA1-4620), anti-NFATc1 (Santa Cruz Biotechnology, sc-7294), and anti-NFATc2 (4G6-G5) (Santa Cruz Biotechnology, sc-7296). The signal was amplified and detected using a peroxidase-conjugated goat anti-rabbit, anti-mouse, or anti-rat immunoglobulin G and the Enhanced Chemiluminescence-Plus detection system (Amersham Pharmarcia Biotech, Uppsala, Sweden).
Affinity purification of the RCAN1 protein complex
The tandem epitope-tag affinity purification procedure for isolating protein complexes from native tissues was slightly modified from previous reports (Gu et al. 1999; Nikolaev et al. 2003) . Mouse brain tissue (3 g) was homogenized in 30 ml HB buffer (10 mM Tris, 10 mM KCl, 1.5 mM MgCl 2 , pH 7.3) containing protease inhibitors (Sigma, P8340) using a tissue grinder, then kept on ice for 20 min followed by centrifugation at 1,0009g for 12 min. NaCl and Triton X-100 were added to the collected supernatant to final concentrations of 133 mM and 0.2 %, respectively, followed by incubation on ice for 1 h with occasional mixing. After centrifugation at 15,0009g for 30 min, the supernatant was passed through a 0.45 lm Millipore filter. Anti-FLAG M2 affinity beads (Sigma, A2220), 200 ll slurry, were added to the supernatant and gently rotated at 4°C overnight. The beads were spinwashed five times with 0.5 ml HB133 buffer (HB buffer, 133 mM NaCl, 0.2 % Triton X-100, protease inhibitors) at 1,0009g and eluted twice at 4°C with 150 ll HB133 containing FLAG peptide (Sigma, F4799) at a concentration , 150 mM NaCl, 0.2 % Triton X-100, 10 % glycerol, and fresh proteinase inhibitor cocktail]. The whole-cell extracts were immunoprecipitated with anti-FLAG M2 affinity beads or anti-HA agarose beads. After three washes with lysis buffer, the bound proteins were eluted using FLAG-peptide or HA-peptide. The eluted material was resolved by SDS-PAGE and detected by Western blotting with antibodies as indicated.
Luciferase reporter assays
Jurkat leukemia cells (5 9 10 5 /2 ml in one well) were transfected in six-well plates with plasmid DNAs using FuGENE 6 (Roche Diagnostics, Indianapolis, IN). After 24 h of incubation, 2 ml medium was added to each transfected well, mixed, and separated equally into two new wells. One set of transfected cells was stimulated with PMA (10 ng/ml) and ionomycin (1 lM) for 8 h. Cells were harvested and the luciferase activity was measured using the Dual Luciferase Reporter Assay System Kit (Promega, Madison, WI) according the manufacturer's protocol.
Electrophysiological studies
Electrophysiological measurements were performed essentially as previously described (Puzzo et al. 2008) . Transverse hippocampal slices 400 lm thick were maintained in an interface chamber at 29°C. They were perfused with saline solution (124 mM NaCl, 4.4 mM KCl, 1 mM Na 2 HPO 4 , 25 mM NaHCO 3 , 2 mM CaCl 2 , 2 mM MgSO 4 , 10 mM glucose) continuously bubbled with 95 % O 2 and 5 % CO 2 . Slices were permitted to recover for at least 90 min before recordings. Field-excitatory postsynaptic potentials (fEPSP) were monitored by placing the recording electrodes in CA1 stratum radiatum. Basal synaptic transmission was assessed by plotting the stimulus voltage (V) against the slope of fEPSP to generate input-output relations. For long-term potentiation (LTP) experiments, baseline stimulation was delivered every minute at an intensity that evoked a response of *35 % of the maximum evoked response. Baseline responses were recorded for 30 min prior to beginning experiments in order to assure stability of the response. LTP was induced using theta-burst stimulation (four pulses at 100 Hz, with the bursts repeated at 5 Hz, and each tetanus including three 10-burst trains separated by 15 s).
Statistical analysis
Survival in mouse experiments is represented by KaplanMeier curves, and significance was estimated with the logrank test using GraphPad Prism ver. 4 software (GraphPad Software, Inc., La Jolla, CA).
Results
Production of BAC-Tg mice carrying the human RCAN1 (DSCR1) genomic locus BAC RP11-272A3, from the RPCI library (Osoegawa et al. 2001) , is a 185 kb clone containing the entire RCAN1 gene flanked by 44 kb of upstream DNA and 42 kb of downstream DNA (Fig. 1a) . This BAC does not include any other complete genes; although the 5 0 portion of the KCNE1 gene is present on the BAC, these sequences encode only the first noncoding exon. We used BAC recombineering to insert a tandem HA-FLAG peptide sequence immediately preceding the stop codon in the last exon. BAC-Tg mice were created by injecting purified BAC DNA into male pronuclei of fertilized B6/CBA oocytes. To test the resulting progeny, we used eight pairs of PCR primers specific for the 5 0 , middle, and 3 0 regions of the human RCAN1 gene, as well as southern blotting with a RCAN1 probe, which identified three founder mice with intact BAC DNA (Fig. 1b, c) . Phosphor imaging of southern blots simultaneously hybridized with similarly sized DNA probes specific for the human RCAN1 and the mouse Col6a1 gene allowed us to estimate that the BAC DNA copy numbers in the lines derived from founders #1, #2, and #3 were approximately 1, 3, and 5, respectively (Fig. 1b) . We refer to these transgenic lines as RCAN1
BAC-

Tg1 , RCAN1
BAC-Tg2 , and RCAN1 BAC-Tg3 , respectively. The RCAN1 BAC-Tg1 and RCAN1 BAC-Tg2 lines transmitted the transgene in Mendelian proportions, with no evidence of embryonic or adult mortality. However, founder #3 only transmitted the BAC-Tg to males, which was presumably due to integration of the BAC on the Y chromosome. Because this high-copy line overexpressed the transgene at supraphysiological levels, we chose to perform most of our subsequent experiments using the lower-copy
RCAN1
BAC-Tg1 and RCAN1 BAC-Tg2 lines. Data reported here are from these BAC-Tg mice in the C57BL/6 genetic background after C5 generations of backcrossing to wild-type C57BL/6. We have not observed any deaths or morbidity over several years of work with these lines, with the mice routinely maintained up to 9 months of age.
Copy number-dependent RCAN1 protein expression in RCAN1 BAC-Tg mice To find out whether the major regulatory elements for RCAN1 expression are present on the RP11-272A3 BAC, we surveyed mRNA expression in multiple adult tissues of the three transgenic lines. We hybridized Northern blots sequentially with cDNA probes matching the human and murine RCAN1 orthologs. Since we designed the probes to span regions of these genes that have divergent nucleotide sequences, there was no cross-hybridization on these blots. For each of the three Tg lines, the mRNA expression pattern of the human RCAN1 gene in the BAC-Tg mice was found to be similar, though not identical, to that of the endogenous murine Rcan1 gene ( Supplementary Fig. 1 ). A transcript of the expected size was seen in all organs except the liver, which showed a shorter transcript (but normal protein size, see below).
To verify that the observed expression of human RCAN1 mRNA in the transgenic mice in fact led to overproduction of RCAN1 protein, we performed western blots using total protein lysates from adult tissues of the BAC-Tg mice and their wild-type nontransgenic littermates. We first probed these blots with anti-HA antibody recognizing the tagged human RCAN1. The highest expression of the tagged RCAN1 protein was found in the brain. We also found significant expression in other relevant tissues, namely, the thymus and heart (Fig. 2a) . Although the liver mRNA is a shorter size, it gives rise to the correct-size protein. In addition, the BAC-Tg gives rise to both the long 38 kDa and short 27 kDa isoforms of RCAN1 protein. Western blotting of brain lysates in successive generations of mice has shown that expression of the epitope-tagged RCAN1 protein has been stably maintained in these mouse lines for over more than 14 generations.
In addition to tissue specificity, another criterion for testing the inclusion of key regulatory elements in a BACTg construct is copy number-dependent expression of the gene under consideration. If the observed expression increases with increased copy number, this suggests that the transgene is at least partially insulated from the cis-effects of chromatin at its sites of integration. By western blotting of total protein from adult brains, we in fact observed copy number-dependent expression, with the RCAN1 protein levels paralleling the BAC DNA copy numbers (19, 39, and 59) in the three BAC-Tg lines (Fig. 2b, Supplementary Fig. 2 ). Probing these blots with an antibody-recognizing RCAN1 protein of both human and mouse origin, we could establish the ratio of RCAN1 expressed from the BAC-Tg to that of the endogenous mouse protein, leading to estimates of 1.59, 29, and 59 in the RCAN1 BAC-Tg1 , RCAN1 BAC-Tg2 , and RCAN1
BAC-Tg3
lines, respectively.
Purification of the RCAN1 protein complex
Using BAC recombineering we had tagged the transgenic RCAN1 with an HA-FLAG peptide epitope, thus making it possible to affinity-purify RCAN1 protein complexes from native tissues of the BAC-Tg mice. To reduce the possibility of unspecific binding due to overexpression of the bait in these experiments, we used brain lysates from the low-copy-number RCAN1 BAC-Tg1 mice. After sequential FLAG and HA affinity pull-downs and elutions, the final protein preparations were separated on SDS-PAGE gels (Fig. 3a) and the individual bands were cut out from the gel and subjected to LC-MS analysis.
The major proteins identified in this core RCAN1 complex are listed in Fig. 3b . Both the catalytic and regulatory subunits of the CaN phosphatase are major components of the complex, a finding that is consistent with extensive previous evidence that RCAN1 is a regulator of CaN (Fuentes et al. 2000; Rothermel et al. 2000) . Consistent with CaN being a Ca 2? /calmodulin-activated enzyme, we found that calmodulin is also present in the core RCAN1 complex. Glycogen synthase kinase 3 beta (GSK3b) is also present in substantial amounts in the complex. A previous report showed that GSK3b can phosphorylate RCNs, which are homologs of human RCAN1, in yeast (Hilioti et al. 2004) , and in mammalian cells it has also been shown that RCAN1 (Calcipressin-1) is a phosphoprotein (Genesca et al. 2003) .
These data show a highly stable physical interaction between GSK3b and RCAN1. The bait human RCAN1 appears as one of the major bands on the gels of this complex, as expected, and, importantly, the endogenous mouse RCAN1 protein coexists in the complex, thus indicating that the epitope-tagged human RCAN1 protein has properties very similar to the endogenous mouse RCAN1. The LC-MS data further revealed that [90 % of the GSK3b in the complex is phosphorylated at Tyr-216, a known activating mark for this enzyme, and that approximately 60-70 % of human and mouse RCAN1 in the complex is phosphorylated at Ser-112 (QFLISP-PASPPVGWK). Lastly, to find out whether the binding partners of RCAN1 are similar in different tissues, we used the same protocol to purify the core RCAN1 complex from thymus. The results (Fig. 3c) showed that the pattern of binding partners is very similar in these two different tissues. Lastly, separate experiments using direct immunoprecipitation (IP)-western blotting from brain lysates independently confirmed the physical associations of epitope-tagged RCAN1 with CaN and GSK3b in mouse brain (Fig. 3d) . Fig. 2 Western blot analysis confirming epitope-tagged RCAN1 expression in brain, thymus, and heart, with expression proportional to copy number of the BAC-Tg. a Total proteins were prepared from BAC-Tg and wild-type mouse tissues and blotted with anti-HA antibody to recognize the epitope-tagged human RCAN1 protein. The HA antibody detects the expression of two isoforms of RCAN1 in brain, thymus, and heart. The Coomassie blue-stained gel is shown as a loading control. b Western blot probed with a RCAN1-specific antibody that recognizes RCAN1 proteins of both human and mouse.
Comparison of the three BAC-Tg mouse lines shows copy-numberdependent RCAN1 protein expression
The LOC73419 protein interacts substoichiometrically with RCAN1 An evolutionarily conserved but as yet poorly characterized protein, LOC73419 (1700052N19Rik; human homolog C6orf211), with a molecular weight of 47 kDa, was detected substoichiometrically in the RCAN1 complex (Fig. 4a) . To verify whether the interaction was specific, we expressed fusion proteins FLAG-RCAN1 and HA-LOC73419 in 293-transformed kidney cells. HA-LOC73419 coimmunoprecipitated with FLAG-RCAN1 in protein lysates from these cells (Fig. 4a) . Considering that the affinity purification of the RCAN1 complex was done from brain lysates, we also expressed these two tagged proteins by transfection into Neuro-2a neuroblastoma cells, which revealed a more efficient co-IP than in the non-neuronal 293 cells (Fig. 4b) . As a negative control in these transfections, we included a plasmid encoding an unrelated protein, FLAG-Usp21, which did not bind to HA-LOC73419 at all (Fig. 4b) . These results support a bona fide albeit substoichiometric interaction between these two proteins; however, the biochemical and physiological importance of this interaction remain to be determined. Relevant to this question, when we carried out promoter-reporter assays in Neuro-2a cells cotransfected with pIL2-luciferase and increasing amounts of the HA-LOC73419 plasmid, we found a small but statistically significant increase in reporter activity, indicating a modest net positive effect of LOC73419 on the activity of this CaNsensitive promoter (Supplementary Fig. 3 ).
Stability of the RCAN1 core complex with CaN and GSK3b
When we subjected the purified RCAN1 protein complex to gel-filtration chromatography on Superose 6, we found that RCAN1, CaN, and GSK3b coeluted in the same fractions (Fig. 5a ), indicating that the three proteins exist in a stable complex that remains intact through several affinity and gel filtration steps carried out over several days in buffers with physiological salt concentrations. There is apparently a higher-order stoichiometry in the complex, as the predicted molecular weight corresponding to the peak fractions is substantially greater than the sum of these three proteins. Conversely, since GSK3b has diverse signaling functions in the cell involving a large number of protein Fig. 3 Purification of the RCAN1 complex from lowcopy-number BAC-Tg mouse brain and identification of its major protein components. a Wild-type and RCAN1
BAC-Tg1
whole-mouse-brain lysates in hypotonic buffer were subjected to tandem affinity purification using anti-FLAG and anti-HA beads. The final protein preparation was resolved by SDS-PAGE and individual bands were excised and analyzed by LC-MS. b List of proteins identified in each band by LC-MS. c Silver-stained gel of tandem affinity-purified material from thymus and brain lysates showing that the RCAN1 complex is similar in these two tissues. d Western blots of the purified complex, independently confirming that the bait RCAN1-HA-FLAG and two major interacting proteins CaN and GSK3b were correctly identified by LC-MS substrates other than RCAN1 and CaN, we next asked what percentage of total cellular GSK3b is bound in the RCAN1 complex. Transgenic brain lysates were prepared using lysis buffer with physiological NaCl concentration (HB133; see Methods) and separated on the same gel-filtration column. This procedure revealed that only a small fraction of total cellular GSK3b, crudely estimated from the immunoblots as about 1 %, is in the RCAN1 complex (data not shown). Similarly, although CaN is a major component of the RCAN1 complex, by comparing the amount of RCAN1-bound CaN in the IP material to the total input, we estimate that only about 1 % of total cellular CaN is stably associated with RCAN1 (Fig. 5b) . Lastly, the protein PRMT5, which constituted a minor but reproducible band (#1) in the affinity-purified material, is a known false-positive interactor in tandem epitope tag affinity purification procedures and is probably not a specific binding partner of RCAN1 since in gel filtration it does not elute in the same fractions as RCAN1 and GSK3b (Fig. 5c ).
RCAN1 enhances CaN activity in the RCAN1 protein complex RCAN1 has been extensively studied as a regulator of CaN, a protein phosphatase that is crucial for the nuclear factor of activated T cells' (NFAT) signaling pathway. However, there have been ostensibly contradictory findings in terms of its stimulatory versus inhibitory effects on CaN activity (Fuentes et al. 2000; Sanna et al. 2006 ). Initially, we used an enzymatic assay to measure total CaN activity in extracts from whole brain and hippocampus. This assay measures the activity of all cellular CaN, including both RCAN1-bound CaN and the large amount of intracellular non-RCAN1-associated CaN. At the level of sensitivity of this colorimetric phosphatase assay, we did not detect significant differences between wild-type and Tg mice (data not shown). We therefore used the same enzymatic assay to measure the activity of total cellular CaN by IP with anti-CaN antibody and compared the results with assay of the activity of transgenic RCAN1-bound CaN, immunoprecipitated from Tg mouse tissues with anti-HA antibody. To control for possible effects of the anti-CaN antibody on CaN activity, the whole-cell lysates in the latter procedure were preincubated with anti-CaN antibody prior to the IP with anti-HA antibody. These experiments showed that the activity of RCAN1-bound CaN is dramatically higher than that of total cellular CaN (Supplementary Fig. 4 ). This result is consistent with previous conclusions from Rcan1/Rcan2 double-knockout mice, in which CaN activity is abrogated (Sanna et al. 2006) , and it suggests that one fraction of total CaN in the mouse brain exists in a low-activity state, not bound to RCAN1, while another fraction exists in a high-activity RCAN1-bound state.
Deficient hippocampal LTP in RCAN1 BAC-Tg mice
RCAN1 is a candidate gene for contributing to cognitive disability in people with DS via its dose-dependent overexpression and consequent effects on CaN activity in neurons. In particular, the CaN phosphatase, which is regulated in part by RCAN1, is well known to be essential for synaptic plasticity (Winder and Sweatt 2001; Zeng et al. 2001) . As our RCAN1 BAC-Tg lines showed appropriate expression of the BAC-Tg in whole brain and in isolated hippocampus, we undertook experiments to test long-term potentiation (LTP), an electrophysiological surrogate for memory, in hippocampal slices from the RCAN1 BAC-Tg2 mice. As shown in Fig. 6a , this experiment revealed a clear gene-dosage-dependent impairment of Fig. 4 The protein encoded by the LOC73419 gene interacts substoichiometrically with RCAN1. a Plasmids encoding HA-LOC73419 and FLAG-RCAN1 were coexpressed in 293 cells. After IP of FLAG-RCAN1, HA-LOC73419 is detected. The input lysate for the IP (4 % of total) was loaded in the first lane; comparison with the IP lane shows that the interaction of these two proteins in 293 cells is substoichiometric. b HA-LOC73419 and FLAG-RCAN1 plasmids were cotransfected into Neuro-2a cells with an unrelated control expression plasmid, producing FLAG-USP21 and serving as a negative control. IP was performed as in a. Ha-LOC73419 is more efficiently pulled down by IP of FLAG-RCAN1. The negative control FLAG-USP21 shows no binding to Ha-LOC73419. The first lane shows 1 % input; comparison with the results in a suggests that HA-LOC73419 interacts more efficiently with FLAG-RCAN1 in Neuro2a cells than in 293 cells LTP, with the greatest impairment in brains from mice that had inherited the BAC-Tg from both parents (estimated Tg copy number 6) and a more modest impairment, though not achieving statistical significance, in mice with the BAC-Tg inherited from only one parent (estimated Tg copy number 3). Basal synaptic transmission was not affected (Fig. 6b) , indicating that the overexpression of RCAN1 specifically affects synaptic plasticity. We interpret these results as showing perturbation of synaptic plasticity by relatively modest overexpression of the RCAN1 gene and protein, at levels that are slightly increased relative to the situation in human DS brains, where the RCAN1 gene is triplicated. These findings can be reconciled to the lack of increased crude CaN activity in total brain lysates in vitro, and with our observation that a large fraction of total cellular CaN is not RCAN1-bound, by postulating a role for RCAN1 in regulating a specific functionally important subcellular fraction of CaN in neuronal synapses. Importantly, the phenotype of deficient LTP in these BAC-Tg mice proves that the epitope-tagged RCAN1 construct is biologically active, which in turn supports the relevance of our biochemical findings with this tagged construct.
RCAN1 overexpression alters the expression of NFATc1
We next investigated the effect of expression of RCAN1 on the transcription factor NFAT. NFAT is a family that includes NFATc1, NFATc2, NFATc3, and others, which are substrates of CaN (Hogan et al. 2003; Macian 2005) . We prepared mouse embryonic fibroblast (MEF) cells from both Tg and littermate wild-type embryos and used thapsigargin to alter Ca 2? levels in these cells. Thapsigargin activates the calcium/CaN signaling pathway (Stewart et al. 1998) , acting by inhibiting the ATPase pumps on Ca 2? storage organelles, which maintain homeostasis by pumping Ca 2? from the cytosol into these organelles, including the endoplasmic reticulum. Inhibition of pump action causes emptying of intracellular calcium stores and a resultant Ca 2? influx across the plasma membrane via capacitative entry. After exposure to thapsigargin, RCAN1-Tg MEFs reproducibly showed increased expression of NFATc1 ( Supplementary Fig. 5 ), an effect that was consistent across all three BAC-Tg lines. This increased expression of NFATc1 in turn strongly induced the expression of the short isoform of Tg RCAN1 ( Supplementary Fig. 5 ), a finding that is consistent with previous reports that only the expression of short-form RCAN1 is NFAT-dependent (Lange et al. 2004; Yang et al. 2000) .
These data further demonstrate that the epitope-tagged RCAN1 protein produced from the BAC-Tg is active in the cellular context. However, when we carried out Western blotting of whole-brain lysates from the BAC-Tg mice (Tg1 and Tg2 lines) to test for effects of RCAN1 overexpression in vivo on the phosphorylation levels of several known substrates of the CaN phosphatase, namely. DAR-PP32, Tau, CREB, and dynamin, we found no change in steady-state levels of the phosphorylated forms of these proteins (data not shown). These negative results using whole-brain lysates suggest that the effects of changes in RCAN1 levels, within the physiological range relevant to Fig. 5 Stability of the interaction of RCAN1 with CaN and GSK3b. a CaN and GSK3b remain associated with RCAN1 through Superose chromatography of the purified complex. Based on molecular weight markers coeluting in later fractions, the molecular weight corresponding to Superose fractions 21 and 22 is more than the sum of these three proteins in the core complex, indicating higher-order stoichiometry. b Less than 1 % of CaN associates with RCAN1 protein in whole-brain lysate from RCAN1 BAC-Tg1 mice. The amount of CaN in the RCAN1 complex from 200 ll of lysate is compared with the CaN in 5 ll of the original lysate (2.5 % input of the IP amount). c PRMT5 is not a stable binding partner in the core RCAN1 complex. A preparation of the RCAN1 complex from RCAN1 BAC-Tg1 liver lysate was loaded on the same superose column as in a. PRMT5, a known nonspecific binder to affinity resin in HA-FLAG tandem purification experiments, is not stably bound to the RCAN1 complex, as indicated by the lack of coelution DS, on the phosphorylation states of these CaN target proteins are either subtle or, more likely, highly localized to specific anatomical regions and/or subcellular structures (e.g., synapses, neurites), possibilities that can be examined in future experiments with the BAC-Tg mice. RCAN1 overexpression slightly accelerates or has no effect on Myc-driven mammary tumorigenesis
The RCAN1 protein has been implicated in inhibition of tumor growth via an inhibitory role in endothelial cell signaling and tumor angiogenesis--findings that have supported the involvement of RCAN1 gene dosage in the well-known DS phenotype of resistance to solid tumors (e.g., Baek et al. 2009; Minami et al. 2004; Qin et al. 2006) . However, other experimental approaches have yielded results that seem to argue against this hypothesis (Ryeom et al. 2008 ) and other chromosome 21-linked genes, notably ETS2, have also been proposed as tumor suppressors (Reynolds et al. 2010; Sussan et al. 2008; Wolvetang et al. 2003) .
To test the effects of RCAN1 gene dosage on tumorigenesis in our BAC-Tg mice, we first crossed these mice with Tp53 conditional knockout (CKO) mice, p53 flex7 (Chen et al. 2005 . These females were mated with wildtype males to induce pregnancy and cre expression, leading to inactivation of the Tp53 tumor suppressor gene, specifically in epithelial cells of the mammary glands. Thus, the only variable in the resulting cohorts of tumor-predisposed mice was RCAN1 gene dosage (either WT or BAC-Tg). We followed a cohort of 14 female BAC-Tg mice and ten wild-type females for the kinetics (latency) of mammary tumor formation, and obtained tumor tissue from each mouse at necropsy. As shown in Fig. 7 , tumorigenesis in the p53-deficient background was either unaltered or slightly accelerated in the BAC-Tg mice [RCAN1 ; p53 ; WAP cre/? (T 50 = 325 days); p = 0.07, log-rank test]. ; Wap cre/? (T 50 = 325 days)], but the difference was not statistically significant (p = 0.07, log-rank test). Time is depicted in days after birth of the first litter
The adenocarcinomas that form in this mouse model are clonal proliferations of p53-null mammary epithelial cells, which are surrounded by variable amounts of (p53-wildtype) reactive stromal cells. To verify the Tp53 exon 7 deletion in the tumors from our mouse cohort, we used PCR across the floxed exon to assess its deletion in genomic DNA from each tumor. This procedure revealed, as expected, a strong recombined band in all tumors, regardless of the presence or absence of the RCAN1 Tg (Supplementary Fig. 6 ). However, there was a modest but reproducible relative increase in the minor nonrecombined p53 flex7 PCR product from the p53 flex7 :RCAN1 Tg tumors. This result suggests that the p53 flex7 :RCAN1 Tg tumors may have modestly greater numbers of stromal cells (nonrecombined Tp53 CKO allele) compared to the tumors that form in the absence of the RCAN1 Tg--a possibility that we plan to test in the future using quantitative histological analysis. However, as all of the mice in our experiment died from mammary cancers, the survival data clearly show that RCAN1 is not a tumor suppressor when overexpressed at low levels in this in vivo model, without additional potentially cooperating chromosome 21-derived genes.
Discussion
The RCAN1 (DSCR1) gene encodes a key regulator of the cytoplasmic phosphatase CaN, and it is one of several genes on chromosome 21 that are thought to make important contributions to cognitive disability, heart defects, and possibly other phenotypes such as resistance to solid tumors, including breast cancer and neuroblastoma, in human DS. DS is caused by an extra copy of multiple genes on human chromosome 21, and BAC-transgenic mice (Table 1) are excellent models to investigate the contributions of individual chromosome 21-linked genes to the constellation of phenotypic features in this disorder. Here we have reported the generation of three BAC-Tg mouse lines expressing epitope-tagged human RCAN1 in relevant tissues, including brain, heart, and thymus, in a copy number-dependent manner. Our initial set of phenotypic studies described here highlight the full viability of these mice, without major anatomical defects, which is consistent with prior data showing that restoration of the Rcan1 gene to disomy has no impact on developmental anomalies, including heart defects, in trisomy 16 mice, which are a model for DS (Lange et al. 2005 ). Nonetheless, we have shown here that the extra dosage of RCAN1 from the BACTg produces quantitative abnormalities, including impairment of hippocampal LTP in brain slices and increased calcium-dependent induction of NFATc1 expression in MEFs. Deficient LTP in these mice adds to multiple other lines of evidence that cumulatively support a role for RCAN1 triplication in the cognitive disability phenotype of human DS. The above phenotypic measurements also indicate that the epitope-tagged RCAN1 BAC-Tg construct is biologically active, and our biochemical studies by tandem affinity purification show that RCAN1 forms a stable complex with CaN and Gsk3b, plus several other proteins. We have further shown that the CaN in this complex is highly active. Prior discordant findings in the literature of both stimulatory and inhibitory effects of RCAN1 on CaN may be due to differences in the experimental systems utilized, to tissue-specific effects, and to a dose dependence in which RCAN1 becomes inhibitory only at a high RCAN1/CaN ratio. We also found a novel candidate interacting protein, encoded by the LOC73419 gene, which is a component of the RCAN1 complex in vivo. Based on our transfection experiments, this protein-protein association is stronger in Neuro-2a neural lineage cells than in 293T kidney cells, which suggests that cellular context (other proteins and/or post-translational modifications) is important for the interaction. The LOC73419 protein contains a DUF89 domain, for which the function remains to be determined. However, a recent study showed evidence for a growthpromoting role of its human ortholog, C6orf211, in MCF7 breast cancer cells (Dunbier et al. 2011) .
There is agreement in multiple studies that children and adults with DS have a reduced incidence of solid tumors, including neuroblastoma and breast cancer (Hasle 2001) , but the role of RCAN1 as an antiangiogenic tumor suppressor gene in DS needs more investigation (Hesser et al. 2004; Iizuka et al. 2004; Minami et al. 2004; Ryeom et al. 2008) . Our finding that RCAN1 overexpression has no effect or slightly accelerates tumorigenesis in p53-null mouse mammary glands argues against the RCAN1 gene being a breast cancer suppressor, but these data do not rule out such a role. For example, the suppressor activity may be evident only in tumor types that have a stronger vascular dependence or, more likely, it may require additive or synergistic interaction with other chromosome 21 genes such as ETS2, SIM2, and others (Kwak et al. 2007; Sussan et al. 2008; Yang and Reeves 2011) that are also present at an increased dosage in DS. This consideration of genegene interactions is crucial, not only for explaining the decreased solid tumor incidence in DS, but also for gaining a better molecular understanding of the other important aspects of the syndrome, including heart defects, cognitive disability, and early-onset Alzheimer's disease. The stable RCAN1 BAC-Tg lines that we have reported here will be useful for crossing to other transgenic, transchromosomal, and knockout mouse lines (Herault et al. 2012; Liu et al. 2011a, b; Wiseman et al. 2009 ) to identify the critical combinations of genes that account for these phenotypes.
